Though only a few trials have shown the efficacy in a clinical setting, the STAT3 pathway remains a promising drug target for future treatment of pancreatic ductal adenocarcinoma and may help overcome chemotherapy resistance. The gene discussed is STAT3; the disease is pancreatic ductal adenocarcinoma.